Meeting Banner
Abstract #0634

Mapping of Glioma Metabolism Using In Vivo Deuterium Metabolic Imaging (DMI)

Henk M. De Feyter1, Kevin L. Behar2, Peter B. Brown1, Douglas L. Rothman1,3, and Robin A. de Graaf1,3

1Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, United States, 2Department of Psychiatry, Yale University, New Haven, CT, United States, 3Department of Biomedical Engineering, Yale University, New Haven, CT, United States

Deuterium Metabolic Imaging (DMI) is a novel approach providing high 3D spatial resolution metabolic data from both animal models and human subjects. DMI relies on 2H MRSI in combination with administration of 2H-labeled substrates. In a rat glioma model we show how DMI combined with administration of [6,6’-2H2]-glucose and [2H3]-acetate allowed spatial mapping of differences in metabolism between normal brain and glioma. DMI data after infusion of 2H-labeled glucose revealed high glucose uptake and lactate production but limited glucose oxidation in glioma. Furthermore, DMI revealed acute therapeutic effects of a drug (dichloroacetate) targeting glucose oxidation.

This abstract and the presentation materials are available to members only; a login is required.

Join Here